Our partnership with the uMed research platform
Attenborough Surgery is currently working with a research technology partner known as uMed. Their accredited platform enables us to provide you with research opportunities that are highly relevant to your health circumstances.
Without the use of uMed’s technology we may not have the time to find and engage patients that meet the requirements of the studies. This would therefore mean many patients would miss out on their chance to participate in ground-breaking research.
For further information on uMed please visit their website at www.umed.io or email [email protected]
Practice Privacy Notice Statement
Supporting Research Activity
Attenborough Surgery uses Umedeor Ltd (uMed) as a data processor to support research and care support activity. This includes accessing and secure hosting of health record data for the purpose of identifying patients that are eligible for specific research or care support projects. uMed also contacts those patients on behalf of the practice via SMS, letter, email or telephone to provide more information about the study, and to collect additional information to assess your eligibility for a certain study.
Your consent will be required before any practice data is shared externally with researchers. uMed applies the national opt-out to practice data it receives so if you wish your data is not processed for research you can do so by visiting https://www.nhs.uk/your-nhs-data-matters/.
For further information on uMed please visit their website at www.umed.io or email [email protected]
The FLASH Study
Although there are several treatment options already available for asthma, some individuals may still have difficulty controlling their symptoms.
Attenborough Surgery is taking part in the FLASH study which is investigating whether a medication called Atuliflapon can improve symptoms for patients living with moderate to severe uncontrolled Asthma.
This study is recruiting male and female participants between the age of 18-55 years of age with a confirmed asthma diagnosis.
Attenborough Surgery is working with our research technology partner uMed to invite patients to this study.
If you meet the study criteria, you may receive a text message, email or letter asking whether you would like to take part.
Participation is entirely voluntary and you can opt out at any time.
If you have any questions about this study please contact the uMed nurse support team at [email protected].
The PILLAR study
The World Health Organization estimates that 65 million people worldwide have moderate to severe COPD. Although maintenance therapies are available to help maintain regular breathing, some people still have symptoms or experience exacerbations which can result in a hospital admission, even when prescribed a combination of all 3 therapies.
Attenborough Surgery is taking part in the PILLAR study which aims to understand whether a new investigational add-on medication will reduce airway inflammation and improve COPD symptoms in people on maintenance triple therapy.
The study is recruiting male or female participants over the age of 40 years, with an established diagnosis of COPD. To be eligible for this study participants will have had chronic bronchitis for at least 3 months in each of the prior two consecutive years, or had a chronic productive cough within the previous year.
Attenborough Surgery – Study text for practice websites
Attenborough Surgery is working with our research technology partner uMed to invite patients to this study.
If you meet the study criteria, you may receive a text message, email or letter asking whether you would like to take part.
Participation is entirely voluntary and you can opt out at any time.
If you have any questions about this study please contact the uMed nurse support team at [email protected].
RSVoice
RSV is frequently associated with the risk it brings to young children, but the virus also poses a high risk for adults with pre-existing health conditions and older adults.
Hospitalisation rates due to RSV in people with chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), coronary artery disease (CAD), asthma, and diabetes have been found to be higher than the rates in patients without these conditions.
This study aims to evaluate the safety and immune response of a new vaccination aimed at preventing RSV infection in high risk adults.
Attenborough Surgery – Study text for practice websites
Attenborough Surgery is working with our research technology partner uMed to invite patients to this study.
If you meet the study criteria, you may receive a text message, email or letter asking whether you would like to take part.
Participation is entirely voluntary and you can opt out at any time.
If you have any questions about this study please contact the uMed nurse support team at [email protected].
